Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (Ticker: TNFA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: TNF is a clinical-stage pharmaceutical company developing Isomyosamine (an oral TNF-α inhibitor for autoimmune diseases and frailty) and Supera-CBD (a synthetic CBD analog). The company has no commercial product revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,920,938) | $(19,365,689) |
| Net Loss Attributable to Common Stockholders | $(4,710,803) | $(21,344,896) |
| Operating Expenses | $4,344,457 | $6,154,268 |
| Research & Development Expenses | $2,418,985 | $1,600,042 |
| General & Administrative Expenses | $1,735,982 | $2,088,632 |
| Cash and Cash Equivalents (End of Period) | $207,553 | $536,026 |
| Marketable Securities (End of Period) | $3,605,508 | $8,345,082 |
| Total Assets | $17,151,103 | $21,421,084 |
| Working Capital | $(397,585) | N/A |
| Stockholders' Equity | $5,277,287 | $97,805 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly from $(19.4M) in the prior year to $(2.9M) in the current period. This improvement is primarily due to the absence of large non-cash losses on the issuance of preferred stock and warrant liabilities that occurred in 2024.
- Operating Expenses: Total operating expenses decreased by approximately $1.8M year-over-year. This was driven by a $764k reduction in stock-based compensation and a $353k reduction in general and administrative costs (partially offset by a $819k increase in R&D expenses related to Phase 2b study costs).
- Liquidity Position: Cash and marketable securities decreased from $8.5M at year-end 2024 to $3.8M at June 30, 2025. The company utilized marketable securities to fund operations, resulting in a net cash decrease of $34,399 for the six-month period.
- Capital Structure: Significant conversions of Series F, F-1, and G Preferred Stock into Common Stock occurred during the period, increasing common shares outstanding from 3.4M to 29.4M. Full ratchet anti-dilution provisions triggered adjustments to conversion and exercise prices down to $0.1832 per share.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With a working capital deficit of $(397,585) and negative operating cash flows of $(4.7M) for the six months ended June 30, 2025, the company requires additional financing to sustain operations for the next 12 months.
- Nasdaq Compliance: The company received a deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price. It has a compliance period until September 15, 2025, to regain compliance or risk delisting.
- Unusual Items: The 2024 period included significant non-cash losses ($8.8M) related to the issuance of Series F-1 and G Preferred Stock and associated warrants. These items are not present in the 2025 period. Conversely, 2025 included a $1.3M gain from the change in fair value of derivative liabilities.
- Outlook: The company is advancing the Phase 2b clinical trial for Isomyosamine and has initiated studies evaluating its impact on lean muscle mass during GLP-1 treatment. No revenue is expected until regulatory approval and commercialization are achieved.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of current cash ($207k) and marketable securities ($3.6M) against the burn rate of ~$4.7M per six months to assess immediate funding needs.
- Dilution Risk: Review the impact of the full ratchet anti-dilution provisions which adjusted conversion prices to $0.1832, potentially resulting in massive share issuance upon conversion of remaining preferred stock and warrants (over 234M warrants outstanding).
- Nasdaq Status: Monitor the company's ability to meet the $1.00 minimum bid price requirement by September 15, 2025, to avoid delisting.
- Preferred Stock Obligations: Assess the terms of Series F, F-1, and G Preferred Stock, including 10% annual dividends (payable in cash or stock) and installment redemption requirements.
- Clinical Progress: Confirm the status and funding of the Phase 2b Isomyosamine trial and the GLP-1 muscle preservation study.